Form 4: Contineum Therapeutics CMO Sells Shares

Contineum Therapeutics' CMO and Head of Development, Tim Watkins, exercised stock options and immediately sold 3,611 shares of Class A Common Stock.

Summary

• Tim Watkins, CMO & Head of Development at Contineum Therapeutics, Inc. (CTNM), reported transactions on December 29, 2025.
• He acquired 3,611 shares of Class A Common Stock by exercising stock options at a price of $4.50 per share.
• Immediately following, he disposed of these 3,611 shares of Class A Common Stock at a weighted average price of $12.0627 per share, with individual sales ranging from $12.00 to $12.39.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 23, 2025.
• Following these transactions, Tim Watkins beneficially owns 0 shares of Class A Common Stock directly and 256,389 stock options.

Sentiment

Score: 5

Explanation: Neutral. While an executive selling shares can be seen negatively, the transaction was pre-planned under a 10b5-1 plan, which mitigates concerns about opportunistic selling based on new information. It represents a monetization of vested compensation.

Positives

• The executive realized a significant gain by exercising options at $4.50 and selling at an average of $12.0627.
• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing personal holdings rather than an immediate reaction to new information.

Negatives

• An executive selling shares could be perceived negatively by investors, as it reduces their direct equity stake in the company.
• The sale of all acquired shares immediately after exercise suggests a desire to monetize compensation rather than increase long-term holdings.

Future Outlook

The remaining 256,389 stock options will continue to vest in 36 equal monthly installments following the initial vesting of one-half of the option shares on October 28, 2025, subject to the reporting person's continuous service.

Industry Context

Insider transactions, particularly sales by executives, are closely watched by the market as they can provide insights into management's perception of the company's valuation or future prospects. However, transactions executed under a Rule 10b5-1 plan are generally viewed as less indicative of immediate sentiment, as they are pre-scheduled to avoid accusations of trading on material non-public information.

Stakeholder Impact

• Shareholders: May interpret the sale as a signal, though the 10b5-1 plan reduces the immediate negative implication. It represents a reduction in direct insider ownership.

Next Steps

• Remaining stock options will continue to vest in 36 equal monthly installments.
• The reporting person undertakes to provide full information regarding the number of shares sold at each separate price within the reported range upon request.

Key Dates

Recommendation

While the sale by a key executive could be a minor negative signal, the transaction was pre-scheduled under a 10b5-1 plan, which suggests it's part of a personal financial strategy rather than a reaction to new company-specific information. Without additional context on the company's performance or strategic direction, this Form 4 alone does not warrant a change from a 'hold' position.

Keywords

Contineum Therapeutics, CTNM, Tim Watkins, Insider Trading, Form 4, Stock Option Exercise, Share Sale, 10b5-1 Plan, Executive Compensation